J Cancer 2018; 9(1):174-181. doi:10.7150/jca.21605
Exploration of the optimal treatment regimes for Esthesioneuroblastoma: a single center experience in China
1. Department of Radiation Oncology, The First Affiliated Hospital, Sun Yat-sen University;
2. Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University;
3. Department of Radiotherapy, cancer center of Guangzhou medical university, Guangzhou 510080, P.R. China;
4. Department of Organ transplantation, The First Affiliated Hospital, Sun Yat-sen University;
5. Department of Radiation Oncology, Cancer Center of Sun Yat-sen University, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.
* These authors contributed equally to this work.
Yuan Y, Ye J, Qiu H, Niu S, Wen B, Wang D, Cao X, Ren Y. Exploration of the optimal treatment regimes for Esthesioneuroblastoma: a single center experience in China. J Cancer 2018; 9(1):174-181. doi:10.7150/jca.21605. Available from http://www.jcancer.org/v09p0174.htm
BACKGROUND: Esthesioneuroblastoma (ENB) is an uncommon neoplasm arising from the olfactory mucosa. The optimal treatment regimen for ENB remains unclear. This study aims to evaluate its clinical features, long-term outcomes and explore optimal treatment patterns.
METHODS: Clinical data of consecutive 44 ENB patients were reviewed retrospectively. The correlation between clinical features and treatment approaches were analyzed, with several prognostic factors explored meanwhile.
RESULTS: The age of onset of ENB showed a bimodal distribution, with peaks at 10~20 and 50~60 years. The median follow-up time was 84 months (range, 27~198 months).The 5-year overall and progression free survival rates were 42.7% and 39.1%, respectively, with 10-year rates of 28.9% and 21.7% respectively. Overall, 19 patients developed recurrent disease. Patients undergoing surgery combined with adjuvant radiotherapy had significantly higher 5-year overall survival (67.5% vs. 33.3%, P=0.043) and progress-free survival (60.0%vs. 18.7%, P=0.008) than those receiving other treatment approaches. No-Skin-involved ENB was associated with markedly better 5-year overall survival (45.5%vs.0 %, P=0.038) and progress-free survival (31.3% vs. 0 %, P=0.001) compared with skin-involved tumor.
CONCLUSIONS: ENB is a rarely malignant tumor with high probability of locoregional recurrence and poor survival. Surgical resection followed by radiotherapy has been shown to achieve optimal local control and overall survival.
Keywords: Esthesioneuroblastoma, Multimodality, Surgery, Radiotherapy, Survival.